News
2022-02-14
The four steps FUJIFILM Diosynth Biotechnologies is taking to impact the future of biopharma manufacturing
That was nearly two years ago as the pandemic hit. Overnight, the CDMO leader had to invent new ways of orchestrating their essential formulation and manufacturing supply chains. Facing a surge of demand from biotechs entering the clinic, the company also invested big in new facilities and technologies.
Read more2022-01-19
Pneumagen Raises £3.8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)
St Andrews, UK – 19th January 2022 – Pneumagen, a clinical stage biotech company developing Neumifil, a pan-antiviral, intranasal drug for the prophylaxis and treatment of viral respiratory tract infections (RTIs), today announced it has raised a further £3.8m to advance clinical development and manufacturing of its lead product Neumifil.
Read more2021-11-30
aTyr Pharma and FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement for aTyr’s Lead Therapeutic Candidate ATYR1923
aTyr Pharma and FUJIFILM Diosynth Biotechnologies Announce Manufacturing Agreement for aTyr’s Lead Therapeutic Candidate ATYR1923
Read more2021-10-13
LEXEO Therapeutics and FUJIFILM Diosynth Biotechnologies Announce Collaboration to Support Development and Manufacturing of Gene Therapies for Genetic Diseases
Read more2021-09-13
FUJIFILM Diosynth Biotechnologies and NeuExcell Therapeutics enter manufacturing agreement to rapidly advance NXL-001, a potential neuro-regeneration gene therapy to treat ischemic cortical stroke
FUJIFILM Diosynth Biotechnologies (FDB) will provide essential drug substance and drug product manufacturing, under accelerated timelines, for NeuExcell’s first-in-human clinical studies Drug substance manufacturing will be carried out in FUJIFILM Diosynth Biotechnologies state-of-the-art cGMP mammalian manufacturing facility in College Station, Texas
Read more2021-07-29
Introducing Landmark Bio and Appointment of Ran Zheng as CEO
Zheng will lead the construction of the new, state-of-the-art biomanufacturing facility that kicks off today (July 29) in Watertown, ma and will begin opening in 2022.
Read more2021-04-26
GENE BIOTHERAPEUTICS PARTNERS WITH FUJIFILM DIOSYNTH BIOTECHNOLOGIES TO MANUFACTURE GENERX [Ad5FGF-4] PHASE 3 ANGIOGENIC GENE THERAPY PRODUCT CANDIDATE FOR REFRACTORY ANGINA
Read more2020-08-17
CPI partners with Perceptive Engineering and FUJIFILM Diosynth Biotechnologies to improve efficiencies in biologics manufacture
CPI has announced a partnership with Perceptive Engineering and FUJIFILM Diosynth Biotechnologies. The companies will develop a data-driven solution to improve efficiencies during downstream biologics processing, reducing the cost of manufacturing life-saving therapies.
Read more2020-07-23
NOVAVAX AND FUJIFILM DIOSYNTH BIOTECHNOLOGIES INITIATE LARGE SCALE MANUFACTURING OF COVID-19 VACCINE CANDIDATE
Novavax, Inc. and FUJIFILM Diosynth Biotechnologies announced today an agreement to manufacture bulk drug substance for Novavax’ COVID-19 vaccine candidate.
Read more2020-06-17
Lassen Therapeutics Launches to Discover and Develop Novel Antibody Therapeutics Including Lead Program Targeting IL-11 to Treat Fibrosis and Oncology
Read more2020-06-08
Greffex Inc. Signs Manufacturing Contract with FUJIFILM Diosynth Biotechnologies to Produce Vaccines
Read more2020-06-04
“READY TO SAVE THE WORLD” WITH MASS VACCINE MANUFACTURING
On the show, Chancellor Sharp interviewed Dr. Gerry Farrell, chief operating officer of FUJIFILM Diosynth Biotechnologies, Texas, based in College Station
Read more2020-06-01
Tonix Pharmaceuticals Announces FUJIFILM Diosynth Biotechnologies to be Manufacturing Partner for COVID-19 Vaccine Candidate TNX-1800
Read more2020-05-07
Developing a Biomanufacturing Platform to Fill a Need
As a contract development and manufacturing organization (CDMO), FUJIFILM Diosynth Biotechnologies’ scientists and engineers need to offer flexible solutions to changing customer requirements.
Read more2020-04-09
Fujifilm announces the start of a phase II clinical trial of its influenza antiviral drug “Avigan® Tablet” for COVID-19 patients in the U.S.
FUJIFILM Corporation announces the initiation of a U.S. phase II clinical trial to evaluate the safety and efficacy of its influenza antiviral drug “Avigan® Tablet” for patients with COVID-19, a respiratory infection caused by the novel SARS-CoV-2 coronavirus.
Read more2018-07-18
A Discussion with Dr. Thomas Page, VP Engineering and Asset Development at Fujifilm Diosynth Biotechnologies
Read more2015-08-25